The treatment landscape for bladder cancer has undergone a rapid evolution in the past five years with the approval of seven new agents. New classes of medications have improved outcomes for many patients who previously had limited treatment options, but there is still much to learn about how to optimize patient selection for these agents and the role of combination therapies. The aims of this review are to discuss these newly approved agents for bladder cancer and to feature promising drugs and combinations-including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates-that are in development.
Keywords: antibody-drug conjugate; immunotherapy; metastatic; muscle-invasive bladder cancer; targeted therapy; urothelial carcinoma.
Copyright: © 2020 Osterman CK and Milowsky MI.